Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Core Insights - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers [3] - The company will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City [1] - Marc H. Hedrick, M.D., the President and CEO, will host one-on-one meetings during the conference [2] Company Overview - Plus Therapeutics is headquartered in Houston, Texas, and is developing advanced therapies for difficult-to-treat CNS cancers, including leptomeningeal metastases and recurrent glioblastoma [3] - The company utilizes image-guided local beta radiation combined with targeted drug delivery to enhance clinical outcomes [3] - Plus Therapeutics has established a supply chain through strategic partnerships for the development, manufacturing, and potential commercialization of its products [3] Subsidiary Information - CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, focuses on developing proprietary laboratory tests to identify tumor cells that have metastasized to the CNS [4] - The CNSide™ CSF Assay Platform allows for quantitative analysis and molecular characterization of tumor cells in cerebrospinal fluid, aiding in the management of patients with leptomeningeal metastases [4] - CNSide™ is planned for commercialization in the U.S. in 2025 [4]